Connection

Gary Gilkeson to Proteinuria

Back to Details
This is a "connection" page, showing publications Gary Gilkeson has written about Proteinuria.
Gary Gilkeson
Connection Strength
1.030
Proteinuria
  1. Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice. PLoS One. 2020; 15(3):e0230499.
    View in: PubMed
    Score: 0.169
  2. Novel mechanism for estrogen receptor alpha modulation of murine lupus. J Autoimmun. 2019 02; 97:59-69.
    View in: PubMed
    Score: 0.154
  3. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One. 2013; 8(5):e64650.
    View in: PubMed
    Score: 0.106
  4. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. J Investig Med. 2008 Oct; 56(7):911-9.
    View in: PubMed
    Score: 0.076
  5. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol. 2008 Aug; 128(2):259-68.
    View in: PubMed
    Score: 0.075
  6. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol. 2004 Nov 15; 173(10):6481-9.
    View in: PubMed
    Score: 0.058
  7. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol. 2004 Sep 15; 173(6):4171-8.
    View in: PubMed
    Score: 0.058
  8. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004 Jan; 65(1):129-38.
    View in: PubMed
    Score: 0.055
  9. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB ? NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis Rheumatol. 2021 08; 73(8):1478-1488.
    View in: PubMed
    Score: 0.046
  10. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000 Jan 15; 164(2):786-94.
    View in: PubMed
    Score: 0.042
  11. Soluble CD16 in the treatment of murine lupus nephritis. Clin Immunol Immunopathol. 1998 Jul; 88(1):91-5.
    View in: PubMed
    Score: 0.038
  12. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997 Apr; 83(1):86-92.
    View in: PubMed
    Score: 0.034
  13. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med. 1996 Apr 01; 183(4):1389-97.
    View in: PubMed
    Score: 0.032
  14. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant. 2013; 22(12):2279-90.
    View in: PubMed
    Score: 0.025
  15. Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. Clin Exp Immunol. 2010 Nov; 162(2):362-71.
    View in: PubMed
    Score: 0.022
  16. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus. 2010 Nov; 19(13):1502-14.
    View in: PubMed
    Score: 0.022
  17. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol. 2007 Aug; 293(2):F555-64.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.